Search results
Results From The WOW.Com Content Network
Singulair was a blockbuster product for Merck after its launch in 1998, offering relief Exclusive-US FDA finds widely used asthma drug impacts the brain Skip to main content
Montelukast, sold under the brand name Singulair among others, is a medication used in the maintenance treatment of asthma. [6] It is generally less preferred for this use than inhaled corticosteroids. [6] It is not useful for acute asthma attacks. [6] Other uses include allergic rhinitis and hives of long duration. [6]
The medical uses for Cysteinyl-leukotriene type 1 receptor antagonists are for chronic and prophylactic treatment of asthma. [3] [9] [10] Other indications have been approved by the FDA for montelukast and they are used for the prevention of exercise-induced bronchoconstriction (EIB), relief of symptoms of allergic rhinitis (AR) that is for relief of seasonal allergic rhinitis and perennial ...
Singulair, a popular asthma medication, could be linked to severe side effects, including suicide, a study from the FDA found. Popular asthma drug Singulair could be linked to mental health side ...
This article originally appeared on Medical News Today. We’ve rounded up this past week’s most noteworthy health and well-being news, focusing on nutrition, aging, and general well-being.
Medical News Today is a web-based outlet for medical information and news, targeted at both the general public and physicians. All posted content is available online (>250,000 articles as of January 2014), and the earliest available article dates from May 2003. The website was founded in 2003 by Alastair Hazell and Christian Nordqvist. [1]
Mast cell activation syndrome (MCAS) is a term referring to one of two types of mast cell activation disorder (MCAD); the other type is idiopathic MCAD. [1] MCAS is an immunological condition in which mast cells, a type of white blood cell, inappropriately and excessively release chemical mediators, such as histamine, resulting in a range of chronic symptoms, sometimes including anaphylaxis or ...
FDA news: Trump administration pauses communication from CDC, other health agencies FDA approval of Journavx comes after 2 drug trials. Journavx was evaluated in two random double-blind ...